Algorithms based on prostate‐specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false‐postitive PSA results in prostate cancer screening
暂无分享,去创建一个
Anssi Auvinen | Chris Bangma | A. Auvinen | J. Hugosson | U. Stenman | M. Hakama | P. Finne | C. Bangma | Matti Hakama | Jonas Hugosson | R. Finne | Ulf-Håkan Stenman | Patrik Finne | Ralf Finne
[1] U. Stenman,et al. Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. , 1999, Clinical chemistry.
[2] H. D. de Koning,et al. Health‐related quality of life in patients with screen‐detected versus clinically diagnosed prostate cancer preceding primary treatment , 2001, The Prostate.
[3] F. Schröder,et al. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. , 1997, Urology.
[4] O. Nilsson,et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.
[5] R. Renzetti. The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update , 1999 .
[6] T. Tammela,et al. Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. , 2002, Urology.
[7] V. Nelen,et al. Prostate volume and cancer in screening programs , 1997, The Prostate.
[8] O. Nilsson,et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. , 1993, The Journal of urology.
[9] F. Schröder,et al. The European Randomized Study of Screening for Prostate Cancer (ERSPC): An Update , 1999, European Urology.
[10] J. Hugosson,et al. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. , 2000, Urology.
[11] P. Walsh. Results of conservative management of clinically localized prostate cancer. , 1994, The Journal of urology.
[12] J. Hugosson,et al. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam Region) , 1999, The Prostate.
[13] U. Stenman,et al. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. , 1993, Clinical chemistry.
[14] David W. Hosmer,et al. Applied Logistic Regression , 1991 .
[15] B. G. Blijenberg,et al. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. , 1995, Urology.
[16] P Finne,et al. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. , 2000, Urology.
[17] A. Zlotta,et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. , 2001, The Journal of urology.
[18] T. Tammela,et al. Three-year results of the Finnish prostate cancer screening trial. , 2001, Journal of the National Cancer Institute.
[19] Klaus Jung,et al. Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. , 2002, Clinical chemistry.
[20] W. Catalona,et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. , 1995, JAMA.
[21] Martin T. Hagan,et al. Gauss-Newton approximation to Bayesian learning , 1997, Proceedings of International Conference on Neural Networks (ICNN'97).
[22] Dietmar Schnorr,et al. An artificial neural network considerably improves the diagnostic power of percent free prostate‐specific antigen in prostate cancer diagnosis: Results of a 5‐year investigation , 2002, International journal of cancer.
[23] J. Hanley,et al. The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.
[24] B. G. Blijenberg,et al. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. , 1997, The Journal of urology.
[25] Mesut Remzi,et al. Novel artificial neural network for early detection of prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[27] G Bartsch,et al. The problem of cutoff levels in a screened population , 2001, Cancer.
[28] David J. C. MacKay,et al. Bayesian Interpolation , 1992, Neural Computation.
[29] U. Stenman,et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.